Platelet Function Testing: Which Test, and How to Apply? - Current Limitations and Future Perspectives - Young-Hoon Jeong, M.D., Ph.D.
|
|
|
- Angelica Thomas
- 5 years ago
- Views:
Transcription
1 Platelet Function Testing: Which Test, and How to Apply? - Current Limitations and Future Perspectives - Young-Hoon Jeong, M.D., Ph.D. Director, Clinical Trial Center, Gyeongsang National University Hospital; Associate Professor, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Korea.
2 Disclosures Research Grants/Support Otsuka Accumetrics Boehringer-Ingelheim Haemonetics Dong-A Pharmaceutical Han-Mi Pharmaceutical Honoraria/Consulting Otsuka Sanofi-Aventis Daiichi Sankyo Inc Astrazeneca Nanosphere Haemonetics Han-Dok Pharmaceutical
3 Odds ratio Warfarin has a narrow therapeutic window Stroke Therapeutic range 10 Intracranial bleed International normalized ratio VKAs = vitamin K antagonists ACCF/AHA/HRS focused update guidelines: Fuster V et al. Circulation 2011;123:e269-e367; Wann LS et al. Circulation 2011;123: & Circulation 2011;123: April 2012
4 Therapeutic Window of P2Y 12 Inhibitor Tantry US, Aradi D Jeong YH, et al. Consensus for Therapeutic Advances Window. APT. JACC Siller-Matula 2013:E-pub. JM. LPR HPR VerifyNow: 35% 60% 20% PRU (20µM ADP)
5 Relationship btw Platelet Function and Bleeding PCI Cohorts. Tantry US, et al. JACC 2013;E-pub.
6 ADAPT-DES Registry at 1 Year: MV Analysis of ST and Major Bleeding by PRU Adj. Hazard Ratio Q1 (<95) Q2 (95-159) Q3 ( ) Q4 ( ) Q5 (>275) * Maj Bleeding Def/Prob ST referent Note: Bleeding occurred ~7x more frequently than ST *p=0.002; all other p=ns Stone GW, et al. Lancet 2013;382:
7 ADAPT-DES Registry at 1 Year: MV Analysis of Mortality by PRU Quintiles 8,449 PCI pts with VerifyNow PRU after clopidogrel loading No independent association between PRU and mortality at 1 year, possibly due to offsetting risks of ST and Bleeding Stone GW, et al. Lancet 2013;382:
8 Thrombosis Bleeding Navigation - PFT, Genotyping-
9 Platelet Function Testing: Which Test?
10 Available methods for PFT Laboratory-based methods Methods allowing near-patient testing (Platelet-oriented method) (Whole blood test: promising in clinics) TEG LTA What is ideal platelet function test? - Biology: platelet receptor occupancy - Laboratory: validated and POC system VASP? Whole blood vs. Platelet-oriented Multiplate (MEA) VerifyNow - Practice: prediction for clinical events (ischemia and bleeding) Am Heart J 2013;166: : Platelets 2013;24:166-9.: Am Heart J 2012;164:35-42.: JACC 2011;58:2701-2: Heart 2012;98:343: Platelets 2012;23:290-8.: Thromb Haemost 2011;106:263-4: J Thromb Thrombolysis 2010;30: : Eur Heart J 2008;29:
11 Relationship btw R Occupancy and ex vivo Tests LTA VASP-P assay TEG VerifyNow test Sollier et al. Thromb Haemost 2010; 104:
12 VerifyNow Test During Clopidogrel & Ticagrelor ONSET/OFFSET and RESPOND Substudy (n = 760 pairs) Jeong YH, et al. Am Heart J 2012;164:35-42.
13 PRU PRU Ticagrelor vs. prasugrel produces a significantly higher platelet inhibition Platelet Reactivity (in PRU) by Treatment sequence Individual PR values according to treatment Ticagrelor Prasugrel Day 0 Day 15 Day Baseline N=44 Ticagrelor N=43 Ticagrelor Prasugrel Baseline PR lower quartile Baseline PR upper quartile Prasugrel N=42 HTPR Threshold Platelet reactivity is significantly lower in patients receiving ticagrelor compared with prasugrel. Least squares estimates and 95% confidence intervals are presented. PRU platelet reactivity unit(s). Alexopoulos et al. J Am Coll Cardiol 2012;60(3):193-9.
14 VASP-P Assay During Dual Antiplatelet Therapy CAD Patients Treated with Elective PCI (n = 466) Kim IS Jeong YH, et al. Am Heart J 2013;166:
15 Platelet Function Testing: Reversible vs. Irreversible Inhibitor
16 Cumulative Frequency (%) Theoretical Construct for P2Y 12 Reactivity Therapeutic Window Bleeding Ischemic Events 100 Reversible Inhibitor Reversible and Irreversible Inhibitors 0 Do you believe that Irreversible Inhibitor Ticagrelor, more potent P2Y 12 inhibitor, is safer than Prasugrel? P2Y 12 Reactivity Measured by 20 M ADP Aggregation Adapted from Gurbel PA et al. J Am Coll Cardiol. 2008;51:B86
17 PK and PD of Prasugrel vs. Ticagrelor in Rats Concentration-response curve for ADP-induced PA (4h after dosing) ED50 value (20 M ADP): Prasugrel, 1.9 mg/kg vs. Ticagrelor, 8.0 mg/kg Sugidachi A et al. BJP. 2013;169:82-89.
18 PK and PD of Prasugrel vs. Ticagrelor in Rats AV shunt thrombosis model (4h after dosing) 21-G needle into the tail (4h after dosing) Potency Prasugrel vs. Ticagrelor = 4 : 1 Inhibition of Platelet Aggregation = Inhibition of Thrombus Formation ED50: 1.8 mg/kg vs. 7.7 mg/kg ED200: 3.0 mg/kg vs mg/kg = Prolongation of Bleeding Time Sugidachi A et al. BJP. 2013;169:82-89.
19 Clinical Outcome (PCI Cohort) TRITON-PCI vs. PLATO-Invasive (PCI/CABG: 82.1%) TRITON-PCI (14.5 mo F/U) PLATO-Invasive (9 mo F/U) Ticagrelor (n=6732) Clopidogrel (n = 6676) HR (95% CI) P value CV death/mi/stroke 9.0% 10.7% 0.84 ( ) CV death 3.4% 4.3% 0.82 ( ) Non-fatal MI 5.3% 6.6% 0.80 ( ) TIMI major bleed Non-CABG CABG Prasugrel (n=6422) 2.8% 5.3% Clopidogrel (n = 6422) 2.2% 5.9% HR (95% CI) 1.23 ( ) 0.90 ( ) P value CV death/mi/stroke 10% 12% 0.81 ( ) CV death 2% 2% 0.84 ( ) 0.17 Non-fatal MI 7% 10% 0.76 ( ) < TIMI major bleed 2.4% 1.8% 1.27 ( ) Wiviott et al. Lancet 2008;371: : Cannon et al. Lancet 2010;375:
20 Platelet Function Testing: How to Apply?
21 Impact of Platelet Reactivity on Balance Between Efficacy and Safety Ethnicity Angiolillo DJ et al. JACC 2013;62:S21-31.
22 Factors Influencing Thrombotic Events Gurbel P, et al. Eur Heart J 2013;E-pub.
23 GPIIb/IIIa- ADP-Stimulated (MFI) Interleukin-8 (pg/ml) Fibrinogen (mg/ml) GPIIb/IIIa- Unstimulated (MFI) CRP (ug/ml) Platelet-Fibrin Clot-Strength (mm) Relation: Platelet Physiology, Inflammation and Disease Activity AS = Asymptomatic Patients, SA= Stable Angina, UA= Unstable Angina 56 Reactive Platelets 25 Inflammation 72 Prothrombotic State p=.051 P< p=.006 p= P=.002 P= AS SA UA p= P=.22 P=.14 P<.001 P= P= The level 4 of thrombogenecity AS SA UA AS SA UA (vulnerable or sticky blood) and vulnerable AS SA vessel UA A distinct pathophysiological state of heightened platelet reactivity to ADP, platelet activation, inflammation and hypercoagulability, marks the development of symptomatic CV disease from chronic stable disease. Reactive Platelets?? Prothrombotic State 16 0 AS SA UA Unstable Coronary (Hypercoagulability) Artery Disease Inflammation Level of IPA: Stable CAD < NSTE-ACS < STEMI TRIP study. Tantry US, Gurbel PA et al. Platelets. 2010;21: AS SA UA can be different according to the disease activity. Stable CAD < NSTE-ACS < STEMI
24 Efficacy and Safety of Prasugrel vs. Clopidogrel - CYP2C19 LOF Allele Carriage - TRITON TIMI-38: NSTE-ACS cohort LoF allele Prasugrel Clopidogrel Relative risk (95% CI) CV death, MI and Stroke No 9.6% 9.8% 0.98 ( ) Yes 8.5% 15.0% 0.57 ( ) TIMI major or minor bleeds No 4.7% 3.4% 1.38 ( ) Yes 5.5% 3.5% 1.60 ( ) Sorich MJ, et al. J Thromb Haemost 2010; 8:
25 New P2Y 12 Inhibitors vs. Clopidogrel in PCI Bellemain-Appaix, et al. J Am Coll Cardiol. 2010;56:
26 Prasugrel vs. Clopidogrel Therapy after EES Stenting in Unprotected LMCAD Lesion or PCI complexity ( vulnerable vessel ) in stable CAD: Different level of platelet inhibition Migliorini A, et al. Am J Cardiol. 2013;112:
27 Incidence (%) Racial Difference of Stent Thrombosis Risk East Asians vs. Westerners after 1 st DES Similar ST incidence of Asian Registry to RCT Results, but lower to Western Registry 2.3% Bern / Rotterdam 2.9% 2 1.7% % RCTs 0.8% 1.0% AMC 0.7% 0.5% 0.6% j-cypher (Korean Center) 0.5% (Japan registry) Follow-Up (years)
28 Relationship between VerifyNow and Post-PCI Outcome Korea: ROC curve analysis for HPR (total n = 3,844) Study Cohort EP Cutoff ACCEL-LOADING-ACS (Randomized) 1 Zhang et al. (Registry) 2 Ko et al. (Registry) 3 CILON-T (Randomized) 4 Ahn et al. (Registry) 5 NSTE-ACS (n=218); emergent PCI NSTE-ACS (n=228); emergent PCI All comer (n=222); PCI All comer (n=960); DES implantation All comer (n=1226); stenting 1-mo MACE 1-mo MACE 1-mo MACE 6-mo MACE 12-mo MACE PRU 289 % inhibition 12% PRU > 272 PRU 275 PRU Non-AMI: no cutoff AMI: PRU 272 CROSS-VERIFY Different cutoff All comer of (n=809); HPR between 12-mo PRU races 275 (Registry) 6 elective PCI MACE Jin PRU: et al. Western (208~235) STEMI (n=181); vs. Korean 12-mo PRU (253~289) 282 (Registry) 7 primary stenting MACE Influence of different thrombogenecity 1 Jeong YH, et al. TCTAP 2012 LBCT; 2 Zhang HZ, et al. Platelets 2013; 3 Ko YG, et al. Am Heart J. 2011;161:383.; 4 Suh JW, et al. JACC. 2011;57:280.; 5 Ahn SG, et al. JACC Cardio Interv 2012;5:259.; 6 Park KW, et al. Am J Cardiol. 2011;108:1556.; 7 Jin HY, et al. Int J Cardiol 2013;167:1877.
29 ACCEL-BLEED trial Design NAME: the ACCEL-BLEED (A Correlation between on- ClopidogrEL platelet reactivity and BLEEDing events in PCItreated patients) study 305 PCI-treated stable patients (Oct 2009-Jul 2011) - No in-hospital adverse clinical events - Agreed to study protocol - In-hospital platelet function test - Genotyping if agreed DESIGN: Prospective, nonrandomized, single-center clinical observation (Gyeongsang National University Hospital) OBJECTIVE: To examine the relationship between the platelet reactivity and bleeding episodes Post-discharge medication 4 patients: 2 death, 1 ST, 1 TVR Clinical follow-up at 30±5 days (n = 301) - Dedicated questionnaire: compliance, bleeding classification - Pill counting - Interview with attending doctor - Follow-up platelet function test Jeong YH. Featured Clinical Trial. TCT 2011.
30 BARC 2 Bleeding Incidence of Bleeding Events Post-discharge 1-month F/U (n = 301) BleedScore TM Superficial (BARC 1) 67 (22.3%) Internal (BARC 2) 21 (7.0%) Alarming 0 (0%) 20% LTA (20μM ADP) 15% 10% 13.30% P = % 5.30% 5.30% 4.00% 0% Q1 (<34.7%) Q2 ( %) Q3 ( %) Q4 ( %)
31 East Asian Paradox ; Different Therapeutic Zone VerifyNow: LPR HPR 30U 60U 35% 70% 60% 20% 35% 70% PRU (20µM ADP)
32 RCTs: Comparator vs. Standard-dose Clopidogrel East Asian ACS Patients Jeong YH. Curr Cardiol Report 2014;In press.
33 PD Date on Prasugrel (5 vs. 10 mg/d) vs. Clopidogrel (75 mg/d) in Korean Patients 214±69 163±61 80±46 Proposed Therapeutic zone in East Asians Jin HY, et al. Korean Heart Autumn Symposium 2012
34 Perspective: Platelet Function Test Pro - Association between platelet inhibition and clinical events - Several options for antiplatelet agents - Currently available POC system Con - No perfect PFT in biologic, laboratory and practical points - Ischemic and bleeding events are multifactorial - Different therapeutic zone according to the cohort One-APT regimen-fits-all Strategy TDM during digoxin, BP & HR during anti-hypertensive drug HbA1c during OHA and insulin, PT INR during warfarin, Why not during antiplatelet therapy?
Speaker s name: Thomas Cuisset, MD, PhD
Speaker s name: Thomas Cuisset, MD, PhD X I have the following potential conflicts of interest to report: x Consulting: Daiichi Sankyo, Eli Lilly Employment in industry Stockholder of a healthcare company
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
Personalized Antiplatelet Therapy: State of the Art
Personalized Antiplatelet Therapy: State of the Art Paul A. Gurbel, M.D. Sinai Center for Thrombosis Research Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland,
in High-risk PCI Patients?
Lunchtime Activities Is Potent t Oral P2Y 12 Inhibitor Enough to Prevent Thrombotic Events in High-risk PCI Patients? Young-Hoon Jeong, MD M.D., PhD Ph.D. Department of Internal Medicine, Gyeongsang National
Do We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
The Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
Platelet Function Beyond Hemostasis Young-Hoon Jeong, M.D., Ph.D.
Platelet Function Beyond Hemostasis Young-Hoon Jeong, M.D., Ph.D. Director, Clinical Trial Center, Gyeongsang National University Hospital; Associate Professor, Department of Internal Medicine, Gyeongsang
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Ομάδες Εργασίας Φεβρουάριος 2016 Ξανθοπούλου Ιωάννα Καρδιολόγος Επιμ Β ΠΓΝΠατρών Nothing to disclose Platelet function testing (PFT) is helpful in identifying
ACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
Clopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
Cilostazol: Triple Benefits More is Better!
Cilostazol: Triple Benefits More is Better! Matthew J. Price, MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute,
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? Matthew J. Price MD, FACC Director, Cardiac Catheterization Laboratory Scripps
and Ticagrelor Professor of Medicine (Cardiology), Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
Role of Genotyping and Point-of-Care of Testing in Clopidogrel, Prasugrel, and Ticagrelor Ron Waksman, MD Ron Waksman, MD Professor of Medicine (Cardiology), Georgetown University Associate Director, Division
Why and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
Which drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
Μιχάλης Χαμηλός, MD, PhD, FESC
Αντίσταση στα αντιαιμοπεταλιακά. Πως μετράται, πότε πρέπει να εκτιμάται, και πως αντιμετωπίζεται Μιχάλης Χαμηλός, MD, PhD, FESC Πανεπιστημιακό Νοσοκομείο Ηαρκλείου Disclosures Speakers Honoraria: Astra
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
INDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
Antiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
Updated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
Upcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?
Upcoming Evidence and Practice of ptimal Antiplatelet Therapy in DES Era? Polymorphism in Metabolism of Clopidogrel and Its Clinical Implications and Management Alexandra Lansky MD Columbia University
The Role of Triple Antiplatelet Therapy in Patients with High Risk
TAPT: Adjunctive Cilostazol to Aspirin and Clopidogrel The Role of Triple Antiplatelet Therapy in Patients with High Risk Young-Hoon Jeong, MD, PhD Department of Internal Medicine, Gyeongsang National
MONITORAGGIO DELLA FUNZIONE PIASTRINICA DURANTE TERAPIA CON TIENOPIRIDINE
MONITORAGGIO DELLA FUNZIONE PIASTRINICA DURANTE TERAPIA CON TIENOPIRIDINE Rossella Marcucci 30 novembre 2013 CardioLucca 2013 CLOPIDOGREL: A MODEL FOR PERSONALIZED MEDICINE High on-treatment platelet reactivity
Πποβλημαηιζμοί με ηην ανηιαιμοπεηαλιακή αγωγή ζηο οξύ έμθπαγμα ηος μςοκαπδίος με ανάζπαζη ηος διαζηήμαηορ ST.
Patras University Hospital Πποβλημαηιζμοί με ηην ανηιαιμοπεηαλιακή αγωγή ζηο οξύ έμθπαγμα ηος μςοκαπδίος με ανάζπαζη ηος διαζηήμαηορ ST. Dimitrios Alexopoulos, MD, FACC, FESC Cardiology Department, Patras
When and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
Is Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
Antiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
Learning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
Risk of GI Bleeding and Use of PPIs
Risk of GI Bleeding and Use of PPIs ESC 211 August 28, 211 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Associate Professor of Medicine, Harvard
Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
Optimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
P2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
Case Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
Point-of-Care Genetic Testing for Tailored Anti-Platelet Therapy Ready for Prime Time?
Point-of-Care Genetic Testing for Tailored Anti-Platelet Therapy Ready for Prime Time? Robert G. Wilkins, M.D., F.A.C.C., F.S.V.M New Cardiovascular Horizons May 29, 2015 No Disclosures Dual Anti-Platelet
Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές
4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος
DES in primary PCI for STEMI: contra
DES in primary PCI for STEMI: contra Philippe Gabriel Steg Department of Cardiology Hôpital Bichat Claude Bernard, AP-HP Université Paris VII Denis Diderot INSERM U-698 Paris, France Ph. Gabriel Steg -
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
Improving Patient Outcomes: Updated Treatment Strategies in the Management of Acute Coronary Syndrome
Improving Patient Outcomes: Updated Treatment Strategies in the Management of Acute Coronary Syndrome E. Magnus Ohman, MB, FRCPI, FESC, FACC Professor of Cardiovascular Medicine The Kent and Siri Rawson
Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
Controversies in PCI A young cardiologist s perspective
Controversies in PCI A young cardiologist s perspective Antiplatelet Tx, PLT function monitoring should be mandatory CONTRA M. Valgimigli, MD, PhD Ferrara, Italy Euro-PCR Session @ ESC August 30th 2010,
Dual Antiplatelet Therapy: Time for a Paradigm Shift?
Dual Antiplatelet Therapy: Time for a Paradigm Shift? 5 years after PLATO Experience from the Daily Clinical Practice Hans Rickli Goals with antithrombotic treatment Acute coronary syndrome Risk reduction
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
ISAR-CHOICE 2. Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI
ISAR-CHOICE 2 Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Variability in Platelet Response to Clopidogrel Serebruany
Dual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
On admission Acute extensive anterior STEMI
Mr B 52 years old male Smoker No prior known CAD Presents with 1 hour intermittent crushing retrosternal chest pain Transferred by MICU directly to CCU (ASA, Heparin) On admission Intense pain, diaphoretic
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
Upstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia
Upstream P2Y 12 RB Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia Dio può essere dimostrato Le dimostrazioni dell esistenza di Dio IA Dio non può essere dimostrato
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
Joint Meeting of Coronary Revascularization 8 th to 9 th December 2017
B Joint Meeting of Coronary Revascularization 8 th to 9 th December 2017 A Novel Clinical Application Combining Genotyping and Platetlet Function Testing In Patients With Acs - A Case Series Shirley Tan
Stable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
Τicagrelor: Μία διαφορετική χημική κατηγορία αντιαιμοπεταλιακής θεραπείας
Τicagrelor: Μία διαφορετική χημική κατηγορία αντιαιμοπεταλιακής θεραπείας Στοιχεία από πρόσφατες μελέτες Stavros V. Konstantinides, MD, FESC Department of Cardiology Democritus University of Thrace, Greece
Session Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
Prasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
Anti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
The Pharmacogenetics of Clopidogrel
The Pharmacogenetics of Clopidogrel CANNeCTIN Cutting-Edge Pharmacogenetics Symposium May 22, 2009 Marc S. Sabatine, MD, MPH Investigator, TIMI Study Group Associate Physician, Cardiovascular Division,
Diabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
IMMATURE PLATELETS CLINICAL USE
HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,
July ACCP Cardiology PRN Journal Club 7/23/2018
July ACCP Cardiology PRN Journal Club 7/23/2018 Dr. Michael Plazak Dr. Michael Plazak is a PGY2 Cardiology Pharmacy Resident at the University of Maryland School of Pharmacy. He graduated from the University
Measurement of Antiplatelet Therapeutic Efficacy
Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology Research St Vincent Hospital Worcester MA Disclosure
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
GENNARO SARDELLA MD, FACC,FESC
PhaRmacodynamic Effects of Switching therapy in PCI patients with high on Treatment platelet reactivity and genotype variation: high Clopidogrel dose versus Prasugrel (RESET GENE Study). (ClinicalTrials.gov
3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
Robert Storey. Sheffield, United Kingdom
Antiplatelet in ACS Moving beyond clopidogrel Robert Storey Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield and Academic Director and Honorary Consultant Cardiologist,
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
What hematologists should know about VerifyNow
What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted
Journal of the American College of Cardiology Vol. 60, No. 3, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 3, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.050
Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
ADP P2Y12 Receptor Blockade
Is there a need to tailor antiplatelet therapy in diabetes? ADP P2Y12 Receptor Blockade Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
Original Article. Introduction. Korean Circulation Journal
Original Article Print ISSN 1738-552 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Platelet Function Test on Platelet Responsiveness and Clinical Outcome After Coronary Stent Implantation:
The Myth of Class Effect Antithrombotics Christopher Cannon, MD
The Myth of Class Effect Antithrombotics Christopher Cannon, MD Cardiovascular Division Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study
Columbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
Robert Storey. Sheffield, United Kingdom
Breakthrough Antiplatelets and Anticoagulants: Focus on brand new drugs Robert Storey Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield and Academic Director and Honorary
Utility of Pharmacogenomics to Identify and Limit CV Risk. Christopher B. Granger, MD
Utility of Pharmacogenomics to Identify and Limit CV Risk Christopher B. Granger, MD Disclosure Research contracts: AstraZeneca, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company, and Boehringer
Update on Antiplatelet Therapy
Update on Antiplatelet Therapy Christine Ibarra Pharm.D. PGY-1 Baptist Hospital of Miami Objectives Explain the role of antiplatelettherapy in prevention of cardiovascular events Appreciate differences
Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
Belinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
Prasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
Thrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility